Bristol-Myers Squibb Company (BMY) Given Average Recommendation of “Hold” by Brokerages
Bristol-Myers Squibb Company (NYSE:BMY) has been given a consensus rating of “Hold” by the twenty-two ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $64.73.
A number of analysts have recently issued reports on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price target for the company. in a report on Tuesday, August 22nd. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. Finally, Goldman Sachs Group restated a “buy” rating and set a $65.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th.
Bristol-Myers Squibb (BMY) traded up $0.19 on Thursday, reaching $63.47. 4,320,011 shares of the company’s stock were exchanged, compared to its average volume of 4,520,000. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb has a twelve month low of $46.01 and a twelve month high of $66.10. The stock has a market cap of $101,690.00, a price-to-earnings ratio of 21.38, a price-to-earnings-growth ratio of 2.40 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the business earned $0.77 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. sell-side analysts forecast that Bristol-Myers Squibb will post 2.99 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.52%. The ex-dividend date is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of BMY. Connecticut Wealth Management LLC purchased a new position in Bristol-Myers Squibb in the 1st quarter valued at approximately $224,000. Birmingham Capital Management Co. Inc. AL boosted its position in Bristol-Myers Squibb by 4.4% in the 1st quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock valued at $3,860,000 after buying an additional 3,000 shares during the period. HGK Asset Management Inc. boosted its position in Bristol-Myers Squibb by 20.8% in the 1st quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock valued at $16,794,000 after buying an additional 53,221 shares during the period. Investment Partners Ltd. OH ADV boosted its position in Bristol-Myers Squibb by 1.4% in the 1st quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock valued at $1,107,000 after buying an additional 274 shares during the period. Finally, Goelzer Investment Management Inc. boosted its position in Bristol-Myers Squibb by 85.4% in the 1st quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock valued at $4,100,000 after buying an additional 34,735 shares during the period. Hedge funds and other institutional investors own 69.82% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.